Comparative Pharmacology
Head-to-head clinical analysis: NEXESTA FE versus SESQUIENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEXESTA FE versus SESQUIENT.
NEXESTA FE vs SESQUIENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Norepinephrine-dopamine reuptake inhibitor (NDRI); weakly inhibits serotonin reuptake. Also releases norepinephrine from presynaptic neurons.
SESQUIENT is a monoclonal antibody that binds to the IL-23 receptor, inhibiting IL-23-mediated signaling and subsequent activation of inflammatory pathways involved in psoriasis and psoriatic arthritis.
One tablet (containing 1 mg norethindrone acetate and 1.5 mg ethinyl estradiol) orally once daily for 28-day cycle.
Intravenous injection of 20 mg/m² body surface area once every 3 weeks.
None Documented
None Documented
Terminal half-life: 4-6 hours; clinical context: dosing every 4-6 hours for pain.
12 hours (range 10-14 h); allows twice-daily dosing in most patients; prolonged in renal impairment
Renal: 20-30% unchanged; fecal/biliary: 70-80% as metabolites.
Renal: 80% unchanged; Biliary/Fecal: 15% as metabolites; 5% other
Category C
Category C
Iron Supplement
Iron Supplement